Dr. John C. ShershowAdult ADHD PsychiatryBook: (212) 265-4310
Menu

By the editorial team of Dr. John C. Shershow, M.D.Published Data: FDA Drug Shortages database, November 13, 2026Download the data (CSV)Summary figures (CSV)Editorial policy

  • 5ADHD medication products listed by the FDA as currently in shortageFDA Drug Shortages database via openFDA, November 13, 2026
  • 4 years, 1 monthtime immediate-release mixed amphetamine salts tablets have been on the list (first posted October 12, 2022)FDA Drug Shortages database
  • 25 of 219package listings marked unavailable; 59 more are in limited supply and 135 are marked availableFDA Drug Shortages database
  • 0listings for atomoxetine, viloxazine, guanfacine, clonidine or centanafadine in the FDA shortage data, whether current, resolved or to be discontinuedopenFDA drug shortages export

Snapshot of the FDA list as of November 13, 2026. We refresh it monthly; the next refresh is due by December 15, 2026. Pharmacy stock changes faster than any list: call your pharmacy before you need a refill.

Months on the FDA shortage list, as of November 13, 2026
  • Mixed amphetamine salts tablets (immediate release)first posted October 12, 202249
  • Lisdexamfetamine capsulesfirst posted July 14, 202339
  • Lisdexamfetamine chewable tabletsfirst posted July 14, 202339
  • Methylphenidate extended-release tabletsfirst posted July 26, 202339
  • Methylphenidate extended-release patch (film)first posted February 28, 202520

Source: FDA Drug Shortages database (openFDA export). Months counted from the date the FDA first posted the product to the as-of date.

ADHD medication products in shortage and how the FDA marks each package listing, as of November 13, 2026
ProductFirst postedListingsAvailableLimitedUnavailableLatest FDA update
Currently in shortage
Mixed amphetamine salts tablets (immediate release)October 12, 202273401419November 9, 2026
Lisdexamfetamine capsulesJuly 14, 20239057330November 3, 2026
Lisdexamfetamine chewable tabletsJuly 14, 2023181800November 2, 2026
Methylphenidate extended-release tabletsJuly 26, 20233416126November 3, 2026
Methylphenidate extended-release patch (film)February 28, 20254400October 16, 2026
Total
All five products2191355925

A listing is one package (one NDC code) from one manufacturer or distributor. The FDA marks each listing Available, Limited Availability or Unavailable, as reported by the company.

Which products and strengths are hardest to find

Every unavailable listing is for one of two products. Immediate-release mixed amphetamine salts tablets have 19 unavailable listings and 14 in limited supply out of 73, and the unavailable ones span 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and 30 mg, that is, every strength listed. Methylphenidate extended-release tablets have 6 unavailable and 12 limited out of 34.

Lisdexamfetamine capsules have no unavailable listings, but 33 of 90 are in limited supply. All 18 chewable lisdexamfetamine listings and all 4 patch listings are marked available, yet both products remain on the list as current shortages.

What manufacturers report

For listings with a stated reason, the most common is "shortage of an active ingredient" (50 listings). 21 listings say the product is on allocation, meaning the company is rationing supply among its customers. Where companies give an estimated recovery or availability date, the dates range from November 2026 to April 2027; many listings say "TBD" or give no date.

These dates are the companies' estimates as reported to the FDA, not commitments.

Not on the list

The FDA's shortage data have no listings (current, resolved or to be discontinued) for the non-stimulant ADHD medications atomoxetine and viloxazine, or for guanfacine and clonidine. Whether any of them suits a particular person is a separate, clinical question.

Centanafadine (Simtriyo), approved by the FDA on July 24, 2026, is not in the shortage database either. The DEA placed it in Schedule III effective October 30, 2026. We found no confirmed US launch as of November 15, 2026; a pharmacy can say whether it can be ordered. Our centanafadine guide has more on its label and schedule.

Package listings by product strength
StrengthListingsAvailableLimitedUnavailable
Mixed amphetamine salts tablets (immediate release)
5 mg12633
7.5 mg8602
10 mg12633
12.5 mg6402
15 mg11713
20 mg12723
30 mg12453
Lisdexamfetamine capsules
10 mg12840
20 mg13850
30 mg13850
40 mg13850
50 mg13850
60 mg13940
70 mg13850
Lisdexamfetamine chewable tablets
10 mg3300
20 mg3300
30 mg3300
40 mg3300
50 mg3300
60 mg3300
Methylphenidate extended-release tablets
18 mg7421
27 mg7412
36 mg7232
45 mg2110
54 mg7331
63 mg2110
72 mg2110
Methylphenidate extended-release patch (film)
10 mg1100
15 mg1100
20 mg1100
30 mg1100

Mixed amphetamine salts strengths are the total of the four salts (the FDA lists each salt separately). Strengths describe the products listed; they are not dosing information.

How we counted

Data. The openFDA export of the FDA Drug Shortages database, last updated November 13, 2026 (1,580 listings in all). We kept every listing whose generic name contains amphetamine, methylphenidate or lisdexamfetamine; all 219 have the status "Current". The FDA groups listings into products by generic name and dosage form; we show the same 5 products.

Dates. "First posted" is the earliest initial posting date among a product's listings, which matches the date the FDA's own product page shows. "Months on the list" counts whole months from that date to the as-of date.

Availability, reasons and estimates are the FDA fields availability, shortage_reason and related_info, as reported by each company. Company names and contact details are left out of this page and the CSV (a "Distributed by" note becomes "Distributed by another company").

Not on the list. We searched every generic name in the export (statuses Current, Resolved and To Be Discontinued) for atomoxetine, viloxazine, guanfacine, clonidine and centanafadine. Centanafadine's approval date is from Drugs@FDA (NDA 218145) and its scheduling from Federal Register document 2026-22208.

Refresh. We re-download the FDA data and rebuild this page every month. The next refresh is due by December 15, 2026. If it cannot be refreshed, we take the page down rather than leave an old list up.

Limits

  • The FDA list covers shortages reported to the FDA or confirmed by it. A local pharmacy can be out of a product that is not on the list, and can have a listed product in stock.
  • A count of listings is not a count of pills. One package listing can be a large share of the market or a small one, and the FDA does not publish volumes.
  • Availability is reported by the companies and updated on their schedule; the latest FDA update for each product is in the first table.

Sources

  1. FDA, Drug Shortages database. Live database.
  2. openFDA, Drug shortages export. Last updated November 13, 2026.
  3. Federal Register, Schedules of Controlled Substances: Placement of Centanafadine in Schedule III. Published October 30, 2026.
  4. openFDA Drugs@FDA, NDA 218145 (Simtriyo). Approval July 24, 2026.

Cite this tracker

Dr. John C. Shershow, M.D.. (2026). ADHD medication shortage tracker: the FDA list as of November 13, 2026. https://drjohnshershow.com/research/adhd-medication-shortage-tracker/

The table behind this page is free to reuse under CC BY 4.0: credit Dr. John C. Shershow, M.D. and link to this page. Download the CSV or the summary figures (CSV).

More research

Looking for an adult ADHD evaluation in New York or New Jersey?

Dr. Shershow evaluates and treats adults with ADHD located in New York or New Jersey. Call the office, or leave your number and the office will call you.

Prefer a call back?

Leave your number and the office will call you to schedule.

No health details needed. Not for emergencies: call or text 988, or call 911.

Book AppointmentCall (212) 265-4310